返回 
加入收藏
药源性低纤维蛋白原血症临床特征及危险因素的文献分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 药源性低纤维蛋白原血症临床特征及危险因素的文献分析 |
| TITLE： | Literature analysis of clinical features and risk factors of drug-induced hypofibrinogenemia |
| 摘要： | 目的 探讨药源性低纤维蛋白原血症的临床特征及危险因素，为临床合理用药提供参考。方法收集国内外数据库自建库起至2024年12月31日药源性低纤维蛋白原血症回顾性病例分析文献，分析患者性别、年龄、纤维蛋白原（FIB）水平变化，药物种类，药源性低纤维蛋白原血症发生率、发生时间、出血率、临床表现、危险因素及保护因素。结果共纳入回顾性病例分析文献40篇，涉及患者17313例。患者年龄为0.83～78.40岁，男性占比16.90%～81.00%；涉及药品5类、13种，包括替加环素、蛇毒血凝酶、托珠单抗及阿替普酶等。药源性低纤维蛋白原血症的发生率为0～100%，发生时间在用药后2h至9个月，停药后多数患者的FIB水平会恢复；出血率为0～91.30%，包括鼻出血、气道出血、消化道出血及脑出血等；危险因素包括高药物剂量、长疗程、腹腔感染、高龄、低基线FIB水平等；保护因素仅在替加环素研究中提及，包括皮肤和软组织感染及高基线FIB水平。结论药源性低纤维蛋白原血症常发生于替加环素、蛇毒血凝酶、托珠单抗等药物使用中，其临床特征因药而异，危险因素包括高药物剂量、长疗程、低基线FIB水平及高龄等。对于高风险药品，建议个体化给药并监测患者FIB水平。 |
| ABSTRACT： | OBJECTIVE To explore clinical characteristics and risk factors of drug-induced hypofibrinogenemia， providing a reference for rational clinical drug use. METHODS Retrospective case analyses literature on drug-induced hypofibrinogenemia were collected from domestic and international databases from their inception to December 31， 2024. The patients’ gender， age， fibrinogen （FIB） levels before and after treatment， drug types， the incidence of drug-induced hypofibrinogenemia， time of occurrence， bleeding rates， clinical manifestations， risk factors， and protective factors were all analyzed. RESULTS A total of 40 retrospective case analysis studies were included， involving 17 313 patients. Patient age ranged from 0.83 to 78.40 years， with males accounting for 16.90%-81.00%. The involved drugs comprised 5 categories and 13 specific agents， including tigecycline， snake venom hemocoagulase， tocilizumab， and alteplase， etc. The incidence of drug-induced hypofibrinogenemia ranged from 0 to 100%， occurring between 2 hours and 9 months after drug administration， and FIB levels rebounded in most patients after drug discontinuation. The bleeding rate varied from 0% to 91.30%， including epistaxis， airway bleeding， gastrointestinal bleeding， and cerebral hemorrhage. Risk factors included high drug dosage， prolonged treatment duration， abdominal infection， advanced age， and low baseline FIB levels. Protective factors were only mentioned in studies on tigecycline， including skin and soft tissue infections and high baseline FIB levels. CONCLUSIONS Drug-induced hypofibrinogenemia is commonly associated with tigecycline， hemocoagulase， and tocilizumab. Its clinical features vary depending on the drug， and risk factors include high drug dosage， prolonged treatment， low baseline FIB levels， and advanced age. For high-risk medications， individualized medication management and monitoring of FIB levels are recommended. |
| 期刊： | 2025年第36卷第13期 |
| 作者： | 文笑；蔡乐；高奥；朱曼 |
| AUTHORS： | WEN Xiao，CAI Le，GAO Ao，ZHU Man |
| 关键字： | 低纤维蛋白原血症；药源性；纤维蛋白原；药物不良反应；临床特征；危险因素；文献分析 |
| KEYWORDS： | hypofibrinogenemia； drug-induced； fibrinogen； adverse drug reactions； clinical features； risk factors； literature |
| 阅读数： | 3 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
